Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage [2][5]. Core Insights - The company, Lin Qingxuan, is positioned as the leading brand in the high-end facial oil segment, with a market share of 12.4% in 2024, reflecting its strong brand resilience and adaptability through various market challenges [4][20][24]. - The company has demonstrated significant growth, with a projected revenue increase from 2.45 billion RMB in 2025 to 5.50 billion RMB by 2028, indicating a compound annual growth rate (CAGR) of 36.01% [6][5]. - Lin Qingxuan's innovative product strategy, particularly the successful launch of the "Little Gold Pearl Water," showcases its ability to expand its product categories while maintaining a strong brand identity [5][55]. Summary by Sections 1. Company Overview - Lin Qingxuan has evolved into a top brand in the facial oil market since its establishment in 2003, transitioning from wholesale to a fully integrated online and offline retail model [16][24]. - The brand has successfully navigated multiple crises, demonstrating strategic agility and a commitment to high-end positioning [24][30]. 2. Product Differentiation - The company has focused on the Camellia oil product line, which has undergone five iterations since its launch in 2014, solidifying its market position [39][44]. - In 2025, the revenue from essential oil products reached 1.02 billion RMB, accounting for 42% of total revenue, with a year-on-year growth of 128.7% [44][5]. 3. Sales Channels - Lin Qingxuan's online sales have surged, with a 70% contribution to total revenue in 2025, driven by platforms like Douyin [5][12]. - The company has expanded its offline presence, increasing the number of stores to 580 by the end of 2025, with a same-store sales growth of 19.6% in the first half of 2025 [5][12]. 4. Organizational Efficiency - The establishment of a matrix organizational structure has enhanced decision-making efficiency and product development capabilities, allowing for rapid innovation and market responsiveness [5][4]. - The successful launch of new products, such as the "Little Gold Pearl Water," reflects the effectiveness of this organizational model [5][55]. 5. Financial Projections - The company is expected to achieve net profits of 573 million RMB in 2026, 774 million RMB in 2027, and 1 billion RMB in 2028, with respective growth rates of 59.1%, 35.0%, and 29.2% [6][5]. - The projected price-to-earnings (P/E) ratios for 2026, 2027, and 2028 are 14, 11, and 8 times, respectively, indicating a favorable valuation outlook [5][6].

根据上海证券交易所《上海证券交易所上市公司自律监管指引第 3 号行业信 息披露：第十三号——化工》的要求，现将公司 2025 年第四季度主要经营数据 披露如下： 二、2025 年第四季度公司主要产品和原材料的价格变动情况 （一）主要产品价格变动情况 证券代码：603983 证券简称：丸美生物 公告编号：2026-005 广东丸美生物技术股份有限公司 关于2025年第四季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 公司主要原材料有添加剂、水溶保湿剂、液体油脂、乳化剂、表面活性剂、 包装物等。 2025 年第四季度，公司主要产品的价格详见下表： | 主要产品 | 2024 | 年 10-12 | 月平均 | 2025 | 年 10-12 | 月平均 | 变动比率（%） | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 售价（元/支） | | | 售价（元/支） | | | | 眼部类 | | 147.19 | | | 125.50 | ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Insights - The company achieved a net profit growth of 37% year-on-year in 2025, driven by both skincare and makeup segments [5][8] - The total revenue for 2025 was 5.05 billion RMB, representing a year-on-year increase of 30.01% [8] - The company maintains a gross margin of 84.22%, which is relatively stable compared to the previous year [8] Financial Performance - Revenue projections for the upcoming years are as follows: - 2026: 6.49 billion RMB (growth of 28.5%) - 2027: 8.19 billion RMB (growth of 26.3%) - 2028: 9.83 billion RMB (growth of 20.0%) [7] - Net profit forecasts are: - 2026: 1.56 billion RMB (growth of 29.9%) - 2027: 2.01 billion RMB (growth of 28.5%) - 2028: 2.47 billion RMB (growth of 22.9%) [7] - Earnings per share (EPS) is projected to be 3.19 RMB in 2026, 4.10 RMB in 2027, and 5.04 RMB in 2028 [7] Business Segments - Skincare revenue in 2025 was 1.87 billion RMB, up 31.1% year-on-year, with key products contributing significantly [8] - Makeup revenue reached 3.00 billion RMB, also reflecting a 30.0% increase year-on-year, with several products achieving over 1 billion RMB in retail sales [8] - The company is expanding its high-end department store channels and has a total of 445 self-operated counters [8] Market Position - The company has been recognized as the top domestic makeup brand during major shopping festivals on platforms like Douyin [8] - The brand is enhancing its high-end positioning with new fragrance products, contributing additional revenue [8] Profitability and Cost Management - The company’s net profit margin improved to 23.9%, an increase of 1.2 percentage points year-on-year [8] - The sales expense ratio decreased to 48.3%, indicating effective cost management and scale effects [8]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the market index [4]. Core Insights - The company achieved a revenue of 5.05 billion RMB in 2025, representing a year-over-year growth of 30.0%, with a net profit of 1.21 billion RMB, up 36.8% year-over-year [1]. - The growth in revenue and net profit is attributed to the successful performance of major product categories, including cosmetics and skincare, with several products exceeding 1 billion RMB in sales [7]. - The company is expected to continue its growth trajectory, with projected net profits of 1.59 billion RMB, 1.99 billion RMB, and 2.42 billion RMB for 2026, 2027, and 2028, respectively, reflecting growth rates of 32%, 25%, and 22% [7]. Revenue Breakdown - **Cosmetics**: In 2025, revenue reached 3.0 billion RMB, with a year-over-year growth of 30.0%. The average selling price decreased by 1%, while the volume increased by 31% [2]. - **Skincare**: Revenue for skincare products was 1.87 billion RMB, growing by 31.1% year-over-year, with significant contributions from star products [2]. - **Fragrance**: The fragrance segment generated 34 million RMB in its first year, indicating potential for brand development [2]. - **Training Business**: This segment saw a slight decline, with revenue of 150 million RMB, down 2.8% year-over-year [2]. Channel Performance - **Online Channels**: Revenue from online sales was 2.48 billion RMB, reflecting a year-over-year increase of 38.8%, with a customer repurchase rate of 30.3% [6]. - **Offline Channels**: Offline sales reached 2.43 billion RMB, up 24.5% year-over-year, with a repurchase rate of 36.5% [6]. Financial Metrics - The company’s gross margin for 2025 was 84.2%, with a net profit margin of 23.9%, indicating stable profitability [6]. - The projected earnings per share (EPS) for 2026 is 3.24 RMB, with a price-to-earnings (P/E) ratio of 21.14 [8].

Core Viewpoint - The article discusses the launch of Asia's first database for children's skin health by Hai Gui Ba Ba and Southern Medical University, aiming to establish scientific standards tailored to the unique needs of children's skin [3][8][11]. Group 1: Industry Challenges - The children's skincare industry has long relied on adult data and Western standards, leading to a lack of tailored products for Chinese children [3][7]. - Existing skincare evaluation systems are based on adult data, failing to consider the dynamic nature of children's skin development [7][8]. Group 2: Database Initiative - The new database will define children's skin health and create a comprehensive dataset covering all age groups, which will help in accurately characterizing skin development [8][11]. - The initiative aims to shift from adult-centric testing to a model that directly uses children's skin characteristics for product development, addressing ethical concerns and improving product efficacy [8][15]. Group 3: Developmental Stages of Children's Skin - Children's skin development is categorized into three stages: - 0-5 years: "Barrier Dysfunction Period" with thin stratum corneum and high moisture loss [4][6]. - 6-12 years: "Function Consolidation Period" where the skin barrier strengthens [4][6]. - 13-18 years: "Hormonal Transition Period" with fluctuating skin barrier and peak immune maturity [4][6]. Group 4: Research and Innovation - Hai Gui Ba Ba is transitioning from a product developer to a standard setter in the industry, with the goal of influencing national standards for children's skincare by 2025 [11][30]. - The company is focusing on innovative ingredient technologies that cater specifically to children's skin needs, moving from a "subtractive" to an "additive" approach in product formulation [15][17]. Group 5: Technological Advancements - The company has developed three key technologies targeting core areas of children's skincare: repair, acne treatment, and sun protection, supported by top-tier global research [17][19]. - The use of AI and data mining has led to the discovery of new correlations between skin indicators and children's skin health, enhancing product formulation [21][23]. Group 6: Brand Philosophy and Consumer Engagement - The brand emphasizes the importance of children's preferences in product development, advocating for a perspective that prioritizes their experiences over adult standards [27][29]. - The company engages children in the product development process, ensuring that their needs and preferences are directly addressed [29][30].

Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The company reported a revenue of 6.317 billion yuan in 2025, representing a year-on-year growth of 11.2%. The net profit attributable to shareholders was 268 million yuan, marking a return to profitability. The net profit after deducting non-recurring items was 45 million yuan, also indicating a turnaround [2] - The growth in performance is primarily driven by the increase in core business revenue, improvement in gross margin, and higher investment income from fund investments and changes in fair value [2] Revenue Analysis - The company focused on core brands and successfully cultivated three billion-yuan products, significantly enhancing brand momentum. Notable products include: - Baicaojis Big White Mud with a GMV exceeding 200 million yuan - Yuze Dry Sensitive Cream, which saw growth surpassing the overall brand level after its relaunch - Liushen Mosquito Repellent Egg, which effectively captures outdoor economy trends and Gen Z consumption patterns, achieving an 8.2-hour long-lasting effect [3] - The company is enhancing brand building and product upgrades, with increased marketing efforts to strengthen brand recognition and drive high-quality growth [3] Online Business Growth - The company is actively promoting online business development, improving channel efficiency through tiered operations with key influencers and enhancing content quality. The core brand's Douyin self-broadcasting business has shown good growth [4] Profitability Analysis - The gross margin for Q4 2025 was 61.81%, an increase of 10.99 percentage points year-on-year. However, the net profit margin decreased to -10.16% due to an increase in R&D and marketing expenses [5] Investment Recommendations - The company is expected to continue benefiting from strategic adjustments and reforms, with successful product launches and enhanced brand momentum. The revenue forecasts for 2026-2028 are projected at 7.185 billion, 8.058 billion, and 8.864 billion yuan, respectively, with net profits of 339 million, 414 million, and 481 million yuan [6]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future stock performance [4][6][17]. Core Insights - The company achieved a revenue of 5.05 billion yuan in 2025, representing a year-on-year growth of 30.0%, with a net profit of 1.20 billion yuan, up 36.7% year-on-year [1][11]. - The company is recognized as a rare high-end domestic beauty brand with strong brand and product recognition among consumers, indicating significant potential for continued growth in the domestic market [4][16][17]. - The company is actively expanding into the fragrance segment and gradually entering international markets, further enhancing its growth prospects [4][16][17]. Revenue Breakdown - Makeup revenue reached 3.00 billion yuan, accounting for 59.3% of total revenue, with a year-on-year growth of 30.0%. The average price per item was 176.4 yuan, with sales volume increasing by 30.9% to 16.99 million units [2][12]. - Skincare revenue was 1.87 billion yuan, representing 37.1% of total revenue, with a year-on-year growth of 31.1%. The average price per item was 328.3 yuan, with sales volume increasing by 24.6% to 5.71 million units [2][12]. - Fragrance revenue was 0.03 billion yuan, accounting for 0.7% of total revenue, with an average price per item of 309.5 yuan and sales volume of 1.09 million units [2][12]. Channel Performance - Offline channel revenue was 2.43 billion yuan, up 24.5% year-on-year, accounting for 49.5% of total revenue. The average revenue per self-operated counter was 5.60 million yuan, an increase of 16.7% year-on-year [3][13]. - Online channel revenue reached 2.48 billion yuan, growing by 38.8% year-on-year, and accounted for 50.5% of total revenue. Online direct sales were 1.94 billion yuan, up 36.1% year-on-year [3][13]. Financial Projections - The company expects revenues of 6.49 billion yuan, 8.29 billion yuan, and 10.59 billion yuan for 2026, 2027, and 2028, respectively, with corresponding net profits of 1.59 billion yuan, 2.04 billion yuan, and 2.58 billion yuan [4][5][17]. - The projected price-to-earnings (PE) ratios for 2026, 2027, and 2028 are 20 times, 16 times, and 12 times, respectively [4][5][17].

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, highlighting strong performance from key players despite a recent market downturn [2][4]. Core Insights - The cosmetics and medical beauty sector has underperformed the market recently, with the Shenwan Beauty Care Index declining by 2.4% from March 20 to March 27, 2026, compared to a 1.7% decline in the Shenwan A Index [4][5]. - Notable companies such as Maogeping, Shangmei, and Linqingxuan reported significant revenue and profit growth for 2025, with Maogeping's revenue exceeding 5 billion yuan, marking a 30% increase, and Shangmei's revenue growing by 35.1% [4][10]. - Linqingxuan achieved a remarkable revenue growth of 102.5%, doubling its revenue from 12.1 billion yuan in 2024 to 24.5 billion yuan in 2025 [16]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has shown weaker performance compared to the overall market, with specific indices reflecting declines [4][5]. - The Shenwan Cosmetics Index fell by 2.9%, while the Shenwan Personal Care Index increased by 0.5%, indicating mixed performance within the sector [4][5]. Company Highlights - **Maogeping**: Achieved a revenue of 5.05 billion yuan in 2025, a 30% increase, with a net profit of 1.204 billion yuan, up 36.7% [10][11]. - **Shangmei**: Reported a revenue of 9.178 billion yuan, a 35.1% increase, and a net profit of 1.154 billion yuan, up 43.7% [11][12]. - **Linqingxuan**: Revenue reached 2.45 billion yuan, a 102.5% increase, with a net profit of 360 million yuan, up 92.9% [16][17]. - **Shanghai Jahwa**: Revenue of 6.317 billion yuan, an 11.25% increase, and a net profit of 268 million yuan, marking a return to profitability [20][21]. Market Trends - The report notes a strong performance in the e-commerce sector, with significant growth in online sales for major brands [27][30]. - The overall retail sales of cosmetics in China showed a growth of 4.5% in the first two months of 2026, indicating a resilient consumer demand [30][31]. Strategic Recommendations - The report recommends focusing on companies with strong brand matrices and high growth in GMV, such as Maogeping and Shangmei, while also highlighting potential in the mother and baby segment [4][10]. - It suggests monitoring companies with strong R&D capabilities and product pipelines in the medical beauty sector, such as Aimeike and Langzi [4][10].

Summary of the Conference Call for Shangmei Co., Ltd. Company Overview - **Company**: Shangmei Co., Ltd. - **Industry**: Cosmetics and Skincare Key Financial Performance - **2025 Revenue**: Approximately 9.2 billion (up 44% YoY) with a net profit of about 1.15 billion [3] - **Core Brand Performance**: - **Hansu**: Revenue of approximately 7.36 billion (up 32% YoY), contributing 80% of total revenue [3] - **Yiyezi**: Revenue of approximately 880 million (up 134% YoY), contributing nearly 10% of total revenue [3] - **Anmiyou**: Revenue of approximately 200 million (up 63% YoY) [3] - **Online Revenue**: Approximately 8.6 billion (up 40% YoY), accounting for 93-94% of total revenue [2][3] Growth Drivers and Strategies - **Brand Expansion**: - Yiyezi is positioned as a second growth curve targeting the 8-18 age group with acne and skincare products [2] - Plans to launch new IP collaborations, including products with Hello Kitty and Ultraman [4] - **Global Strategy**: - Core team has entered Southeast Asia with plans to establish a factory, currently operating around 6,000 overseas retail points [2][5] - **Product Matrix Expansion**: - Yiyezi's product matrix is expanding with a focus on different age groups, including outdoor products for 6-12 years and acne solutions for 12-18 years [4] Marketing and Sales Strategies - **Hansu's Brand Upgrade**: - Transitioned from a broad product focus to a concentrated strategy on key products like BB cream and high-quality skincare [6] - Utilized a "short drama + self-broadcast + full-channel conversion" model for brand enhancement [2][7] - **User Growth on Douyin**: - Achieved user growth through targeted short dramas and collaborations with influencers, resulting in a tenfold increase in audience size [7] - **Competitive Positioning**: - Positioned the Hongman Waist set as a "big brand alternative" with competitive pricing against international brands [8] Financial Metrics and Projections - **Gross Margin Stability**: - Despite an increase in sales expense ratio from 47% to 58%, the gross margin remained stable at approximately 19% [9] - **Future Financial Outlook**: - Expected revenue growth of about 20% for 2026 and 2027, with net profits projected at 1.35 billion and 1.6 billion respectively [12] Multi-Brand Strategy - **Strategic Framework**: - Implemented a "2+2+2" strategy focusing on skincare, hair care, and maternal-infant sectors, aiming to develop six super brands [10] - **Brand Performance**: - Anmiyou and Yiyezi are gaining traction, with Anmiyou's online sales growing by 160% [10] - The high-end skincare brand TAZU is set to launch in 2026 [10] Additional Insights - **Market Adaptation**: - The company is adapting its marketing strategies to different platforms, with a focus on maintaining brand integrity on Tmall [9] - **Emerging Trends**: - The men's skincare line has shown significant growth, indicating a potential new revenue stream [9] This summary encapsulates the key points from the conference call, highlighting the financial performance, growth strategies, marketing approaches, and future outlook for Shangmei Co., Ltd.

Summary of the Conference Call for Shangmei Co., Ltd. Company Overview - Shangmei Co., Ltd. is a research-driven cosmetics brand management company with over 20 years of operational history. The company's vision is to become an influential global cosmetics company, focusing on a "single focus, multi-brand, globalization" strategy. [3][4] Financial Performance - In 2025, the company achieved a revenue of 9.178 billion (up 35.1%) and a net profit of 1.154 billion (up 43.7%). The gross margin increased to 76.43%, and the return on equity (ROE) reached 40.2%. [2][7] - The company maintained a revenue and profit growth guidance of 25% for 2026, despite facing a public relations crisis in early 2026. [18] Brand Performance - **Han Shu**: Revenue in 2025 reached 7.36 billion (up 31.6%). The brand aims to achieve sales of 10-20 billion by 2030. [2][9] - **New Page**: Experienced explosive growth of 134.2%, reaching 880 million in revenue. [2][9] - **Anmi You**: Revenue in 2025 was 198 million (up 62.7%), with expectations to grow to 3-5 billion in the coming years. [9][21] - **Red Elephant**: Sales decreased due to demographic changes and brand adjustments. [9] Market Strategy - The company is shifting its channel structure towards online sales, which accounted for 93.9% of total sales in 2025. [2][8] - The company plans to expand into Southeast Asia with a localized strategy, having built a factory in Indonesia and set to start sales in 2026. [2][6] Product Development and Innovation - R&D investment reached 225 million (up 24%), focusing on proprietary ingredients like KT-939 for skin whitening. [2][7] - The company has established an AI-driven factory in Shanghai, capable of producing 2 million bottles daily. [4] Brand Matrix and Future Goals - The company has structured its brands into three tiers to mitigate risks: - **First Tier**: Han Shu (10-20 billion target) - **Second Tier**: Brands like New Page and Anmi You (2-8 billion target) - **Third Tier**: Brands like Red Elephant and Codemint (0-2 billion target) [5] Challenges and Recovery - Following a public relations crisis, Han Shu's business has stabilized and returned to positive growth by March 2026. [11][18] - The company is focusing on a "Five Good Strategy" for 2026, emphasizing good branding, ingredients, products, pricing, and experiences. [11] Trends and Future Product Launches - The company observes trends towards high efficacy and emotional value in products, with plans to launch new brands like Hello Kitty and collaborations with medical professionals. [15][16] - The company aims to expand its product lines to cover a broader age range, targeting 0-18 years and beyond. [13][22] Conclusion - Shangmei Co., Ltd. is positioned for significant growth with a robust multi-brand strategy, strong financial performance, and a commitment to innovation and market expansion. The company is adapting to market challenges while maintaining a focus on long-term goals and brand development. [17][24]